Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Five Dock, Australia Clinical Trials

A listing of Five Dock, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (69) clinical trials

Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies

This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-3111 in patients with B-Cell Lymphoid Malignancies.

Phase

1.57 miles

Learn More »

A Study Evaluating Venetoclax in Combination With Azacitidine in Subjects With Treatment-Na ve Higher-Risk Myelodysplastic Syndromes (MDS)

This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating venetoclax in combination with azacitidine in subjects with treatment-nave higher-risk MDS comprising a dose-escalation portion and a safety expansion portion.

Phase

1.57 miles

Learn More »

A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma

Primary Objective: To evaluate the safety and tolerability of subcutaneous (SC) blinatumomab dose administrations Secondary Objectives: To determine pharmacokinetics (PK) with continuous intravenous (cIV) and SC administrations To estimate the maximum tolerated dose (MTD) tested for blinatumomab administered subcutaneously To determine the incidence of anti-blinatumomab antibody formation following SC administration ...

Phase

1.57 miles

Learn More »

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Subjects With B-cell Malignancies

This study is evaluating the safety and preliminary efficacy of BGB-3111 in combination with BGB-A317 in subjects with B-cell lymphoid malignancies.

Phase

2.75 miles

Learn More »

CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer

This is an open-label, multicenter, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of CEND-1 in combination with nabpaclitaxel and gemcitabine administered weekly for three weeks followed by one week off over 28 days. This protocol is designed to evaluate the safety, tolerability, and biologic activity of CEND-1 in patients with metastatic pancreatic ...

Phase

2.75 miles

Learn More »

A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies

Dose escalation of AB928 in combination with mFOLFOX at standard doses will be assessed in participants with advanced metastatic GEC or CRC. In this dose escalation combination study participants will receive oral administration of AB928 as well as iv infusion of mFOLFOX. Dose expansion of AB928 in combination with mFOLFOX ...

Phase

3.25 miles

Learn More »

Study of ARO-APOC3 in Healthy Volunteers Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple doses of ARO-APOC3 in healthy adult volunteers and in patients with severe hypertriglyceridemia and familial chylomicronemia syndrome (FCS).

Phase

3.25 miles

Learn More »

Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetcs and pharmacodynamics of single- and multiple doses of ARO-ANG3 in healthy adult volunteers and in dyslipidemic patients including familial hypercholesterolemia and severe hypertriglyceridemia.

Phase

3.25 miles

Learn More »

A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer

This study consists of 2 Part. In the Part 1 (dose escalation phase), up to 4 dose levels of SHR3680 will be investigated with a sequential "3+3" design (3 or 6 participants in each dose level). There will be a single-dose pharmacokinetic (PK) run-in period (7 days). Following the first ...

Phase

3.25 miles

Learn More »

MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination with MEDI4736 in Adult Subjects with Select Advanced Solid Tumors

Phase

3.25 miles

Learn More »